TMCnet News
Take A Look At Our Newsletter and Sign Up Today!! CLNE,IMGM,GRBG,PVTB,TSYS,CGEN(M2 PressWIRE Via Acquire Media NewsEdge) STOCK MARKETING INC PRESENTS : (NASDAQ: CLNE) Clean Energy Fuels Corp., (OTCBB: IMGM) Imagin Molecular Corp., (PINKSHEETS: GRBG) Green Bridge Industries, Inc., (NASDAQ: PVTB) PrivateBancorp, Inc., (NASDAQ: TSYS) Telecommunications Systems Inc., (NASDAQ: CGEN) Compugen Ltd. www.StockMarketingInc.com To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com email us!! [email protected] or call 1-866-583-8960 ------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: CLNE) Clean Energy Fuels Corp.) LATEST NEWS!! Clean Energy Secures 10-Year Contract at Austin-Bergstrom International Airport to Design, Build, Operate New Compressed Natural Gas (CNG) Fueling Station Airport-Adjacent Public Access Station Will Provide 24/7 Support to New Fleets of Airport Parking Shuttles, Courtesy Vans, and Taxis SEAL BEACH, Calif., Dec 28, 2009 -- The City of Austin, Texas has awarded a 10-year contract to Clean Energy Fuels Corp. (Nasdaq: CLNE) to design, build, and maintain a new public access compressed natural gas (CNG) fueling station located adjacent to Austin-Bergstrom International Airport. The facility will operate 24/7 to support growing fleets of off-airport parking shuttle fleets operated by The Parking Spot and Airport Fast-Park; on-airport courtesy shuttle vehicles deployed by Ampco System Parking; taxicabs that serve the airport; and private CNG fleet vehicles in the area. Construction of the station, located on airport-adjacent Spirit of Texas Drive, is scheduled to begin in February 2010. "The station adds to the airport's ongoing effort to reduce impact on the environment," said Patti Edwards, Operations Director, City of Austin Aviation Department. "The natural gas station expands clean fuel opportunities for the airport and the region." James Harger, Clean Energy Senior Vice President and Chief Marketing Officer, said, "In Austin and throughout the country, Clean Energy is working hard to help reduce health-harming emissions and protect environmental quality. The transition by the airport industry and its allied services to natural gas power for ground transportation is accelerating rapidly, in response to the need to curtail emissions and to reduce dependence on imported oil." Harger explained that natural gas fuel produces up to 30% less greenhouse gas emissions in light-duty vehicles compared to gasoline and up to 23% lower greenhouse gas emissions in medium to heavy-duty applications compared to diesel. Department of Energy Information Administration (DOE/EIA) reports estimate that 98% of the natural gas consumed in the U.S. is sourced in the U.S. and Canada. Located in the Texas State Capital, the Austin-Bergstrom International Airport serves more than eight million passengers annually and has 36 nonstop destinations. With more than 750,000 residents, Austin is the 15th largest city in the U.S. The recently announced Austin Climate Protection Plan mandates that all facilities, fleets and operations in the city will be carbon-neutral by 2020, and 100% of city facilities will be powered by renewable energy by 2012. Clean Energy (Nasdaq: CLNE) is the leading provider of natural gas (CNG and LNG) for transportation in North America. It has a broad customer base in the refuse, transit, ports, shuttle, taxi, trucking, airport and municipal fleet markets, fueling more than 17,500 vehicles at 195 strategic locations across the United States and Canada. Clean Energy owns and operates two LNG production plants, one in Willis, TX and one in Boron, CA, with combined capacity of 260,000 LNG gallons per day and designed to expand to 340,000 LNG gallons per day as demand increases. It also owns and operates a landfill gas facility in Dallas, TX that produces renewable methane gas or biomethane for delivery in the nation's gas pipeline network. Clean Energy also owns BAF Technologies, Inc. of Dallas, TX, a leading provider of natural gas vehicle systems and conversions for taxis, limousines, vans, pick-up trucks and shuttle buses. Please visit www.cleanenergyfuels.com. ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: IMGM - Imagin Molecular Corp.) LATEST NEWS!! IMAGIN Molecular Corporation to Acquire Planet Green Bottle Corporation IMAGIN to Trade Common and Preferred Shares for a Large Block of Positron Corporation Equity and for 100% of the Equity of Planet Green Corporation CHICAGO, Dec 23, 2009 -- IMAGIN Molecular Corporation (OTCBB: IMGM) has agreed in a letter of intent to issue 49% of the post capitalization of IMGM in exchange for 84,000,000 Positron Corporation common shares plus 100% of the equity of the Planet Green Bottle, all IMGM shares to be distributed to shareholders or affiliates of Planet Green. Certain Planet Green shareholders have agreed to accept IMGM Preferred Shares which will be convertible into IMGM common shares only if the new company is successful in achieving milestones of revenue of at least (US) $10, $25, $50 and $100 million annually in any year in the next 7 years. Contingent on achieving the individual milestones, each Class of Preferred Stock will become convertible into 25,000,000 common shares of IMGM. Conversion can be accelerated if the common shares of the new company trade at 50c per share or better for 20 consecutive days during that period. A Planet Green shareholder acquired 20,000,000 IMGM common shares payable in exchange for 10,000,000 Planet Green common shares and 10,000,000 Positron Corporation common shares held by the Planet Green shareholder. The IMAGIN Directors have agreed to recommend a name change of IMGM to Planet Green BioTechnology, Inc. IMAGIN will increase its position as a major shareholder of Positron Corporation, a leading Molecular Imaging company that specializes in nuclear cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from PET (positron emission tomography) scan imaging to radiopharmaceutical distribution. Planet Green Bottle Corp. is negotiating to acquire proprietary additives defined as oxo-biodegradable technology that, triggered by oxygen and UV light (sunlight), can cause the 500 billion PET (polyethylene terephthalate) plastic bottles made annually to biodegrade in a fraction of the estimated 1,000 years. Separately Planet Green plans to develop of its own next generation biodegradable additive for PET plastic bottles and containers. A Planet Green Bottle (PGB) affiliate financed the development by Wells Plastics (UK) of a unique oxo-biodegradable PET (polyethylene terephthalate) plastic bottle. PGB is negotiating contracts around the world to incorporate masterbatch additives into branded water, beverage, health and beauty aids, pharmaceutical and any other PET plastic bottle or container in order to address the reduction of plastics in landfills, ditches, rivers and in the oceans, the world's largest plastic garbage dump. The amalgamation of the two companies is the subject to due diligence and to the approval of the Boards of Directors and shareholders of each company. Nick Havercroft, CEO of Planet Green stated, "Planet Green is experiencing a wave of interest around the world. Planet Green's proprietary additive branded Reverte(TM) can be used in any and all of the 500 billion PET plastic bottles being sold annually, 75% of which are not being recycled. Planet Green is a unique clean tech company in that is targeting to become a solution to breakdown the plastic bottle back to CO2 and biomass. "Planet Green is particularly focused on China where it has a joint venture agreement with Fuli (Weihai), a leading plastics company in Shandong province, China. Fuli has agreed to finance the joint venture expansion across China. Separately Planet Green is identifying and negotiating with chemical compounding firms to develop the next generation of additive to enhance current oxo-biodegradable technology. Planet Green intends to continue to promote its Planet Green logo as a brand enhancer for consumer branded products." About Imagin Molecular Corporation: Imagin Molecular Corporation strategy and focus is dedicated to business opportunities in positron emission tomography (PET) manufacturing and the diagnosis of cancer, heart disease and neurological diseases. PET is an advanced medical diagnostic imaging procedure used by physicians in the detection of certain cancers, coronary disease and neurological disorders including Alzheimer's disease. Imagin Nuclear Partners, a wholly owned subsidiary and is a full-service joint venture molecular imaging partner that will own, operate and administer out-patient medical diagnostic imaging centers that utilizes PET and PET/CT scanning equipment. Imagin Nuclear Partners specializes in using evidence based bioinformatics specifically positioned in the market to provide the maximal cost effective benefit to their joint venture partner and the community. Imagin Molecular Corporation is also the Parent of Cipher Multimedia a new Media Marketing and Distribution Solution Company that provides a Distribution Solution for publishers of digital content. ------------------------------------------------------------------------------------------------------------------------------------------------------------ (PINKSHEETS: GRBG - Green Bridge Industries, Inc.) LATEST NEWS!! Green Bridge Industries, Inc. in Final Stages of Signing Licensing Agreement With Wowgreen International, LLC SARANAC, Mich., Dec 23, 2009 -- Green Bridge Industries, Inc. (Pink Sheets: GRBG) is pleased to announce that the Company is in the final stages of signing a licensing agreement with Wowgreen International, LLC. Through this agreement the Company plans to produce and distribute Wowgreen's non-enzyme based, 2nd generation products. Wowgreen currently has twelve safe, effective, all-natural cleaning products which include laundry detergent, dishwasher detergent, and hand dish soap, amongst others. In addition, due to the holidays, Wowgreen International, LLC plans on finalizing the acquisition of the Company the first week of January, 2010. Wowgreen International, LLC is the provider of safe, green household cleaners that are sold and distributed to consumers through a channel of independent distributors. The company's mission is to free the world of toxic chemicals, one household at a time. Wowgreen's products are manufactured from a proprietary blend of surfactants that provide a safe, effective and all natural cleaning solution for every household need. "We are excited about the immediate sales potential the addition of this product brings to the Company," stated William White, Chairman and CEO of Green Bridge Industries, Inc. The Company recently announced that Wowgreen International, LLC had signed a binding letter of intent with Green Bridge Industries to acquire majority control of the Company for an undisclosed amount, which is to be paid in a combination of cash and stock over time. For more information about Wowgreen International, LLC, please visit: www.wowgreen.net. About Green Bridge Industries, Inc.: Green Bridge Industries, Inc. offers non-toxic, environmentally friendly cleaning products to fit the sanitation needs of the medical, agricultural, military, and retail markets. The Company, through its proprietary technology, has the ability to develop bio-renewable alternative cleaning products, which are superior to the synthetic products currently offered in the marketplace. The Company's products are safe for the surfaces it cleans, the environment, animals and humans. For more information on Green Bridge Industries, visit: www.greenbridgeindustries.com. ------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: PVTB - PrivateBancorp, Inc.) LATEST NEWS!! Webcast of PrivateBancorp, Inc.'s Fourth Quarter 2009 Earnings Conference Call CHICAGO, Dec 28, 2009 -- PrivateBancorp, Inc. (Nasdaq: PVTB) will webcast live its quarterly earnings conference call with financial analysts on January 25, 2010, at 11a.m. EST (10a.m. CST). Access to the call will be available via a link called "Fourth Quarter 2009 Earnings Call" on the investor relations page of PrivateBancorp, Inc.'s Internet site at www.theprivatebank.com. The Company plans to release its fourth quarter 2009 earnings prior to the opening of trading on January 25, 2010. The earnings release also will be posted on the Company's website. The webcast and call will feature a brief discussion of the earnings release, followed by questions from professional investors invited to participate in the interactive portion of the discussion. Parties accessing the webcast will be in a "listen-only" mode. Following the live webcast, an archived replay of the call will be available on the PrivateBancorp, Inc. website beginning approximately two hours after the call ends. The replay will remain available until the first quarter 2010 earnings release is available. About PrivateBancorp, Inc. PrivateBancorp, Inc. is a growing diversified financial services company with 34 offices in 10 states and $12.1 billion in assets as of September 30, 2009. Through its subsidiaries, PrivateBancorp delivers customized business and personal financial services to middle-market commercial and commercial real estate companies, as well as business owners, executives, entrepreneurs and wealthy families. Additional information can be found in the Investor Relations section of PrivateBancorp, Inc.'s website at www.theprivatebank.com. ------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: TSYS - Telecommunications Systems Inc.) LATEST NEWS!! U.S. Marine Corps Funds $8 Million to Procure TeleCommunication Systems Wireless Point-to-Point Link Systems and Services WPPL Order Includes Spare Parts, Field Support Representatives and Extended Maintenance ANNAPOLIS, MD, Dec 28, 2009 -- TeleCommunication Systems, Inc. (TCS) (NASDAQ: TSYS), a leading provider of mission-critical wireless communications, today announced that it has been awarded an additional $8 million in funding from the U.S. Marine Corps for the TCS Wireless Point-to-Point Link (WPPL) systems. WPPL systems provide deployed Marines with secure point-to-point and point-to-multipoint transmission of voice, video and data communications over terrestrial microwave radio links. Under this award, TCS will provide field support representatives and extended maintenance warranty support. In addition, TCS will supply spare parts for the RF and Network packages of the WPPL systems, including sector and directional antennas, modems, routers, router cards and router modules. The TCS WPPL provides Marines with critical last-mile communications and allows them to extend their Local Area Network (LAN) to forward-deployed locations by extending services over terrestrial microwave radio links. It enables Non-Secure Internet Protocol Router (NIPR), Secret Internet Protocol Router (SIPR), Voice over IP (VoIP), Video and Defense Switched Network transmission of vital information. This order was awarded by the Army Project Manager for the Warfighter Information Network-Tactical (PM WIN-T) Commercial Satellite Terminal Program (CSTP) and through the U.S. Army's $5 billion World-Wide Satellite Systems (WWSS) contract vehicle. "Our WPPL system has proven to be a workhorse in-theater," said Michael Bristol, senior vice president of government solutions for TCS. "We continue to field these systems on a regular basis and support the forward-deployed warfighter with critical last-mile communications capability." The TCS SwiftLink(R) family of deployable communications solutions provides multimedia capabilities to convey encrypted voice, video and data. TCS SwiftLink products are highly transportable and ruggedized, with a graphical user interface that facilitates easy set-up and operation. The modularity and "plug and play" interfaces between all RF and Baseband configurations inherent in the SwiftLink product line result in communication solutions tailored to the end-user's specific needs. TCS has established a proven track record over the past decade of providing cost effective, highly reliable solutions to the Department of Defense, Special Operations and intelligence communities, the Department of Homeland Security and the Department of State. The TCS SwiftLink product line meets the critical communications demands of this elite customer set, no matter where or how they deploy. About TeleCommunication Systems, Inc. TeleCommunication Systems, Inc. (TCS) (NASDAQ: TSYS) engineers and delivers highly reliable wireless communications technology. TCS is a leader in wireless text messaging and location-based technology, including E9-1-1 services and commercial applications like navigation that use the precise location of a wireless device, and secure satellite-based communications systems and services. Customers include leading wireless and VoIP carriers around the world, cable MSOs, automotive telematics vendors, and agencies of the U.S. Departments of Defense, State, and Homeland Security. TCS is one of six primary vendors on a $5 billion Army Worldwide Satellite Systems Contract vehicle. For more information, visit www.telecomsys.com. ------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: CGEN - Compugen Ltd.) LATEST NEWS!! Compugen Discovers Drug Target for Treatment of Epithelial Tumors Existence and utility of CGEN-671 predicted in silico through use of Compugen's Monoclonal Antibody Targets Discovery Platform TEL AVIV, Israel, Dec 28, 2009 -- --New Drug Target is splice variant of known cancer drug target Compugen Ltd. (NASDAQ: CGEN) announced today the discovery and experimental validation of CGEN-671, a new drug target for multiple epithelial tumors. CGEN-671 is a membrane splice variant of CD55, a known drug target for gastric cancer for which monoclonal antibody (mAb) therapeutics are in clinical development by others. The potential application of CGEN-671 as a drug target was initially predicted in silico by Compugen through the use of its Monoclonal Antibody Targets Discovery Platform; the predicted molecule was then validated experimentally in multiple epithelial tumors. Epithelial tumors, also referred to as carcinomas, account for approximately 85% of all cancers, including the ten most prevalent cancers in the western world, such as breast, colorectal, lung, ovary, prostate and skin. Compugen has filed patent applications covering this novel splice variant and its various therapeutic and diagnostic utilities. Initial experimental studies confirmed the existence of the predicted CGEN-671 transcript (mRNA) and demonstrated that, compared with normal tissue samples, it is highly expressed in colon carcinoma tissue. Furthermore, in these mRNA experiments, CGEN-671's expression level in various healthy tissues was up to 200 times lower than the expression level of the previously known cancer target CD55, suggesting that the Compugen discovered splice variant should be a superior drug target candidate for cancer treatment. In addition, the in silico prediction of CGEN-671 identified a unique sequence present in CGEN-671's extracellular domain that is not present in CD55. This sequence allows for the development of antibodies that specifically bind to CGEN-671 and do not recognize CD55. Recently concluded immunohistochemistry (IHC) studies, by independent pathologists using CGEN-671 specific antibodies, further confirmed the predicted potential for CGEN-671 to serve as a therapeutic mAb target for colorectal, breast and lung cancer. In these studies, it was shown that CGEN-671 was over expressed in more than 75% of the tissue sections derived from the colorectal cancer samples and had a very low expression in most samples of normal colon tissue. Similar results were seen in breast cancer, where 75% of the tumor samples demonstrated significant over expression. In lung cancer, 50% of the tumor samples had over expression compared with normal tissues. These IHC results from diseased and healthy tissue sections strongly suggest significant potential for CGEN-671 as a drug target for clinical development of various types of mAb drug therapy for colorectal, breast and lung carcinomas, and possibly for additional epithelial derived tumors. Dr. Anat Cohen-Dayag, president and co-CEO of Compugen, stated, "We are extremely pleased to see Compugen's continuing success in utilizing its predictive platforms to discover previously unknown candidate molecules in key areas of unmet medical need. Also, of major significance for us is the fact that we have reached the point where we are now using multiple predictive capabilities in combination to accomplish this. The very exciting discovery and validation of CGEN-671 being announced today as well as the oncology target that is the subject of our recently announced collaboration with Bayer Schering Pharma, are excellent examples of the unique capabilities obtained by combining synergistic predictive platforms, in these cases, alternative splicing and the identification of targets for monoclonal antibodies. In addition, the product candidate discovery platform that led to these oncology target discoveries, along with dozens of other potential mAb drug targets now at various stages of validation, uses both LEADS and MED, two of our most sophisticated infrastructure platforms. After more than a decade building these capabilities, it is of course very gratifying to begin to see the results of these efforts." About Epithelial Tumors Epithelial tumors, also referred to as carcinomas, account for approximately 85% of all cancers, including the ten most prevalent cancers in the western world, such as breast, colorectal, lung, ovary, prostate and skin. Epithelial cells are the cover and lining of every surface or cavity of the body. As well as covering the outside of the body, epithelial cells cover all body organs, e.g., the organs of the digestive system. They also line the body cavities, such as the inside of the chest cavity and the abdominal cavity. There are different types of epithelial cells, and all can develop into different types of epithelial cancers. According to the Cancer Statistics Branch of the NCI in the SEER Cancer Statistics Review in the United States, breast, lung and colorectal cancer are the three most prevalent cancers in the US, with more than 100,000 new cases diagnosed yearly for each. Lung cancer is the leading cause of cancer related deaths in the US, with more than 150,000 deaths each year; colorectal and breast cancer are ranked second and third, respectively, with more than 40,000 deaths in the US annually for each. About Compugen's Monoclonal Antibody Targets Discovery Platform Compugen's Antibody Therapeutic Targets Discovery Platform relies heavily on Compugen's LEADS and MED capabilities, two computational biology infrastructure platforms that serve as core components for the development of Compugen's discovery platforms. The LEADS platform provides a comprehensive view of the human transcriptome, proteome, and peptidome and serves as a rich infrastructure for the discovery of novel genes, transcripts and proteins. It includes extensive gene information and annotation, such as splice variants, antisense genes, SNPs, novel genes, RNA editing, etc. At the protein level, LEADS provides full protein annotation including homologies, domain information, subcellular localization, peptide prediction, and novelty status. The MED Platform is an integrated database composed of the results from more than 40,000 public and proprietary microarray experiments, normalized and organized into approximately 1,400 therapeutically relevant conditions (i.e. normal tissues, malignant tissues, tissues from drug treated patients, etc.). Utilizing a sophisticated query interface, the proprietary MED platform allows the simultaneous examination of the expression of genes and pathways across all 1,400 conditions and tissues as well as all 40,000 microarray experiments. In addition to incorporating MED and LEADS, the mAb Targets Discovery Platform utilizes multiple data sources and algorithms to predict a large number of novel membrane proteins that can serve as targets for antibody therapeutics, such as for various cancer and autoimmune diseases. The selection of appropriate candidates from this large body of predicted membrane proteins is accomplished using sub-modules of algorithms and other computational tools developed specifically for each disease state or protein family. About CD55 CD55, also known as decay-accelerating factor (DAF), is a GPI anchored membrane protein. Binding of CD55 to complement proteins accelerates their decay, and thus disrupts the cascade and prevents damage to host cells. A monoclonal antibody (mAb) targeting CD55 is in clinical development by others for gastric cancer. About Compugen Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen's discovery efforts are based on in silico (by computer) prediction and selection utilizing a growing number of field focused proprietary discovery platforms accurately modeling biological processes at the molecular level. Compugen's growing number of collaborations with major pharmaceutical and diagnostic companies cover both (i) the licensing of product candidates discovered by Compugen during the validation of its discovery platforms and in its internal research, and (ii) "discovery on demand" agreements where existing or new Compugen discovery platforms are utilized to predict and select product candidates as required by a partner. In 2002, Compugen established an affiliate, Evogene Ltd. (www.evogene.com) (TASE: EVGN), to utilize certain of the Company's in silico predictive discovery capabilities in agricultural biotechnology. For additional information, please visit Compugen's corporate website at www.cgen.com. ------------------------------------------------------------------------------------------------------------------------------------------------------------ About StockMarketingInc.com StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed. ((Comments on this story may be sent to [email protected])) (c) 2009 M2 COMMUNICATIONS |